DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18

Sorafenib (SFN) is a multi-kinase inhibitor drug for the treatment of advanced hepatocellular carcinoma (HCC), but its limited efficacy is a major obstacle to the clinical outcomes of patients with HCC. We aimed to explore a novel molecular mechanism underlying the chemosensitivity of HCC to SFN, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Hairun, Li, Luting, Hu, Xinyan, Cai, Jianxun, Hu, Xiaojun, Zhang, Haopei, Zhao, Ni, Xu, Xiwei, Guo, Hui, Pang, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629112/
https://www.ncbi.nlm.nih.gov/pubmed/36310384
http://dx.doi.org/10.1080/15384047.2022.2135960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629112/
https://www.ncbi.nlm.nih.gov/pubmed/36310384
http://dx.doi.org/10.1080/15384047.2022.2135960

Ejemplares similares